What is Acer Therapeutics Financial Strength?
Acer Therapeutics has the Financial Strength Rank of 4.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Acer Therapeutics did not have earnings to cover the interest expense.
As of today, Acer Therapeutics's Altman Z-Score is 0.00.
Competitive Comparison of Acer Therapeutics's Financial Strength
For the Biotechnology subindustry, Acer Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acer Therapeutics's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acer Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Acer Therapeutics's Financial Strength falls into.
Acer Therapeutics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Acer Therapeutics's Interest Expense for the
months ended in Jun. 2023 was $-0.64 Mil. Its Operating Income for the
months ended in Jun. 2023 was $-4.29 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.10 Mil.
Acer Therapeutics's Interest Coverage for the quarter that ended in Jun. 2023 is
| Acer Therapeutics did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Acer Therapeutics's Debt to Revenue Ratio for the quarter that ended in Jun. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Acer Therapeutics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acer Therapeutics (Acer Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
300 Washington Street, One Gateway Center, Suite 351, Newton, MA, USA, 02458
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.
Executives
| Chris Schelling |
director, officer: President and Chief Executive |
C/O ACER THERAPEUTICS INC., 222 THIRD STREET, CAMBRIDGE MA 02142 |
| Steve Aselage |
director |
6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
| Tanya Hayden |
officer: Chief Operating Officer |
300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458 |
| Adrian W Quartel |
officer: Chief Medical Officer |
300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458 |
| Bernard H Paul |
officer: Chief People Officer |
300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458 |
| Jefferson E Davis |
officer: Chief Business Officer |
300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458 |
| John Michael Dunn |
director |
C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128 |
| Donald Joseph |
officer: Chief Legal Officer and Secy |
C/O KALOBIOS PHARMACEUTICALS, INC., 260 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
| John Michael Klopp |
officer: Chief Technology Officer |
ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458 |
| Matthew Seibt |
officer: Chief Commercial Officer |
ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458 |
| Michelle Renee Griffin |
director |
19723 NE 65TH LANE, KIRKLAND WA 98033 |
| Harry S Palmin |
officer: Chief Opp. and Financial Offr |
C/O NOVELOS THERAPUETICS, INC., ONE GATEWAY CENTER,SUITE 504, NEWTON MA 02458 |
| William T. Andrews |
officer: Chief Medical Officer |
ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142 |
| Jason Amello |
director |
500 KENDALL STREET, CAMBRIDGE MA 01824 |
| Salma Jutt-eghbali |
officer: Chief Commercial Officer |
ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458 |
Acer Therapeutics (Acer Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACER has been successfully added to your